Companion Diagnostics
A new age of diagnostic testing is evolving that utilizes patient test result information to customize and guide therapy. Pharmaceutical companies are seeking partners to develop and commercialize new diagnostic tests. Our expertise in the identification, optimization and validation of biomarker assays for all phases of drug development and clinical diagnostic applications makes Pathway Diagnostics an ideal partner for pharmaceutical and biotechnology companies and clinical diagnostic test providers.
Our biomarker assay capabilities enhance the internal capabilities of our pharmaceutical and clinical diagnostic clients.
- Biomarker assay development and validation
- Scientific expertise across many therapeutic and diagnostic technology areas
- Proven track record through our novel biomarker program
- Biomarker clinical trial services
- Diagnostic commercialization through our biomarker reference lab and diagnostic partners
Novel biomarker program leading to companion diagnostics:
- SensiTrop™ HIV Assay
- 5HT2a, 5HTTLPR, DRD2; pharmacogenetic biomarkers
- Fclla; pharmacogentic biomarker
|
